No Data
Dezhan Healthcare (000813.SZ) has repurchased 1.32% of its shares, costing approximately 73.2659 million yuan.
Dezhan Healthcare (000813.SZ) issued an announcement that by February 28, 2025, the company will achieve share repurchase...
Dezhan Healthcare's Unit Applies for Development of Cannabidiol Suspension Granules
Dezhan Healthcare (000813.SZ): The cannabidiol suspension granules of Deyi Pharmaceutical have received an acceptance notice.
On February 27, Gelonghui reported that Dezhan Healthcare (000813.SZ) announced that on February 26, 2025, its subsidiary, Deyi Pharmaceutical Co., Ltd. (referred to as "Deyi Pharmaceutical"), received the "Acceptance Notification" from the National Medical Products Administration for the research and development project application of a Cannabidiol suspension granule for the treatment of rare disease pulmonary arterial hypertension. Cannabidiol (CBD), a cannabinoid naturally found in Industrial Cannabis, is widely used internationally in Pharmaceutical, Cosmetic, food, and manufacturing industries.
Dezhan Healthcare's (SZSE:000813) Earnings Have Declined Over Five Years, Contributing to Shareholders 45% Loss
Dezhan Healthcare (000813.SZ): Cumulatively repurchased 1.32% of shares.
On February 5, Gelonghui reported that Dezhan Healthcare (000813.SZ) announced that as of January 31, 2025, the company had cumulatively repurchased 28,567,500 shares through a dedicated securities account for share repurchase through centralized bidding, accounting for 1.32% of the company's current total share capital, with the highest Fill Price at 3.21 yuan/share, the lowest Fill Price at 2.39 yuan/share, and a total transaction amount of 73,265,889.00 yuan (excluding transaction fees).
Dezhan Healthcare (000813.SZ): The medical beauty raw material products have now begun to generate small batch sales revenue.
On January 15, Gelonghui reported that Dezhan Healthcare (000813.SZ) stated in an investor relations activity that the company's medical beauty raw materials include over thirty kinds of beauty peptide raw materials such as recombinant humanized collagen and compound peptide raw materials. Currently, the company's medical beauty raw materials have begun to generate small-scale sales revenue, and proactive discussions are underway for business collaborations with downstream medical instruments and Cosmetic companies to apply the company's medical beauty raw materials to a wider range of terminal products.
Further Weakness as Dezhan Healthcare (SZSE:000813) Drops 6.1% This Week, Taking Five-year Losses to 63%
